# Adaptive Biotechnologies

Source: https://onco.cc/companies/adaptive-biotechnologies/  
OnCo record `adaptive-biotechnologies` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adaptive Biotechnologies makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in ALL, myeloma, and CLL.

## Summary

Adaptive Biotechnologies, based in Seattle and listed as ADPT, makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in acute lymphoblastic leukaemia, myeloma and chronic lymphocytic leukaemia. clonoSEQ sequences IGH, IGK, IGL and T-cell receptor clonotypes and was the first FDA-cleared next-generation sequencing test for measurable residual disease, in 2018 for ALL and myeloma and in 2020 for CLL; it serves as the MRD endpoint in trials and in routine practice, and the company also runs the T-Detect immune medicine business. OnCo links it to NGS-based MRD testing, to the bottleneck of dormant cells and minimal residual disease, and to ideas on reference materials for residual disease tests. Whether MRD can become a regulatory endpoint for approval is the open question. clonoSEQ has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Seattle, WA
- Type: diagnostics
- Website: https://www.adaptivebiotech.com
- Ticker: ADPT

## Sources

- Official website: https://www.adaptivebiotech.com

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [NGS-based MRD (clonoSEQ and molecular MRD)](https://onco.cc/technologies/ngs-mrd-clonoseq/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/)
- ideas: [Reference materials and open proficiency testing for residual disease tests](https://onco.cc/ideas/idea-bio2-mrd-reference-standards/), [Watch the immune system's response in the blood three weeks in](https://onco.cc/ideas/idea-bio2-tcr-repertoire-early-readout/)
- drugs: [clonoSEQ](https://onco.cc/drugs/clonoseq/)

---
JSON: https://onco.cc/api/v1/entities/adaptive-biotechnologies.json